Patient-Reported Outcomes For Organ Transplant Drugs Could Learn From Other Fields

Researchers in the field of solid organ transplant should try to leverage patient-reported outcomes (PRO) instruments from other therapeutic areas, such as cancer and rheumatology, in their bid to develop new, less toxic, immunosuppressive drugs, US FDA officials say.

Although PRO instruments from other fields will not be a perfect fit in the transplant setting, they can be supplemented...